{
    "info": {
        "nct_id": "NCT03207529",
        "official_title": "Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer",
        "inclusion_criteria": "* Patient is >/= 18 years old.\n* Patient has signed the informed consent form prior to the performance of any screening procedures and is able to comply with protocol requirements.\n* Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\n\n  * At least 4 weeks from prior therapy completion (including radiation and/or surgery to starting the study treatment) * Clinically and radiographically stable CNS tumor at the time of screening and not receive steroids and/or an enzyme inducing anti-epileptic mediations for brain metastasis\n  * Absence of leptomeningeal disease\n* Patient has metastatic breast cancer that is not suitable for surgery or radiation therapy for local disease control at the time of screening.\n* Patient has disease that is hormone-receptor positive (estrogen receptor [ER] and/or progesterone receptor [PR] positive [+], HER-2/neu negative [-]) or triple-negative (ER/PR/HER-2/neu -).\n* Patient has an AR-positive and PTEN-positive tumor as determined by using Clinical Laboratory Improvement Amendments (CLIA) compliant assays to identify AR-positive and PTEN-positive disease (AR positivity is defined as >= 1% of nuclear staining, PTEN positivity is defined as > 0% of nuclear staining).\n* Patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) =< 1 that the investigator believes is stable at the time of screening.\n* Absolute neutrophil count (ANC) >= 1.0 x 10^9/L\n* Platelets >= 100 x 10^9/L\n* Hemoglobin >= 9.0 g/dL\n* Serum creatinine =< 1.5 x upper limit of normal (ULN)\n* Total serum bilirubin =< 1.5 x ULN\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the event of liver metastasis, AST/ALT =< 5 ULN\n* Fasting plasma glucose (FPG) =< 140 mg/dL or =< 7.8 mmol/L\n* Patient is able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter drug absorption, such as malabsorption syndrome or major resection of the stomach or bowels.\n* For dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.\n* For dose-escalation portion of study, patients must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.\n* Patient has a life expectancy of at least 3 months in the opinion of the investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.\n* Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.\n* Patient has a history of seizures or any condition that may predispose to seizures (e.g., prior cortical stroke, significant brain trauma) at any time in the past and/or a history of loss of consciousness or transient ischemic attack within 12 months of the cycle 1, day 1 visit.\n* Patient has uncontrolled diabetes.\n* Patient has a history of another malignancy within 2 years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix.\n* Patient has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy.\n* Patient has had any systemic therapy within 2 weeks prior to initiating study drug.\n* Patient has participated in a prior investigational study within 3 weeks prior to initiating study drug.\n* Patient has completed radiotherapy within 2 weeks prior to treatment initiation.\n* Patient has any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with patient's safety, provision of informed consent, or compliance with the study procedures.\n* Patient has known clinically significant cardiac disease or impaired cardiac function, such as:\n\n  * Congestive heart failure requiring treatment (New York Heart Association grade >= 2), left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or ECHO.\n  * History or current evidence of clinically significant cardiac arrhythmias, atrial fibrillation, and/or conduction abnormality, e.g., congenital long QT syndrome, high-grade/complete arteriovenous blockage.\n  * Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) < 3 months prior to screening.\n* Patient has a QT interval adjusted by the Fridericia formula (QTcF) > 480 msec on screening electrocardiogram (ECG).\n* Patient is currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and whose treatment cannot be either discontinued or switched to a different medication prior to starting treatment with the study drug.\n* Patient has any prior use of PI3K inhibitors.\n* Patient has any prior use of anti-androgen therapies.\n* Patient is currently receiving warfarin or other Coumarin-derived anticoagulant for treatment, prophylaxis, or other reasons. Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed.\n* Patient is currently receiving treatment with drugs known to be strong inhibitors or inducers of isoenzymes CYP3A or CYP2C8. The patient must have discontinued strong inducers for at least 1 week and must have discontinued strong inhibitors before the start of the study treatment. Switching to a different medication prior to initiation of the trial treatment is allowed.\n* Patient has impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).\n* Patient has known positive serology for human immunodeficiency virus (HIV).\n* Patient has any other condition that would, in the investigators' judgment, preclude the patient's participation in the clinical study due to concerns about safety or compliance with clinical study procedures; e.g., infection/inflammation, intestinal obstruction, inability to swallow oral medication, social/psychological complications.\n* Patient has a history of noncompliance to medical regimens or is unable to grant consent.\n* Female patients of childbearing potential have positive urine or serum pregnancy test no more than 7 days prior to starting study drug.\n* Female patients of childbearing potential are not willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study. Highly effective contraception is defined as:\n\n  * Surgical birth control/sterilization (such as male vasectomy or female sterilization).\n  * Birth control pills, injections, implants, or patches.\n  * Intrauterine devices (IUDs).\n  * Two barrier methods (male condom and female diaphragm, cervical cap, or sponge) in combination with a spermicide.\n  * Highly effective contraception must be used by both sexes during the study and must be continued for 6 months after the last dose of study treatment. (Women of not childbearing potential: post-menopausal [age > 55 years with cessation of menses > 12 months or < 55 years but not spontaneous menses for at least 2 years or < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of \"postmenopausal range\" for the laboratory involved] or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).\n* Female patients who are breast-feeding.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patient has metastatic breast cancer that is not suitable for surgery or radiation therapy for local disease control at the time of screening.",
            "criterions": [
                {
                    "exact_snippets": "metastatic breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not suitable for surgery or radiation therapy for local disease control at the time of screening",
                    "criterion": "suitability for surgery or radiation therapy for local disease control",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter drug absorption, such as malabsorption syndrome or major resection of the stomach or bowels.",
            "criterions": [
                {
                    "exact_snippets": "Patient is able to swallow and retain oral medication",
                    "criterion": "ability to swallow and retain oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "does not have any clinically significant gastrointestinal abnormalities that may alter drug absorption",
                    "criterion": "clinically significant gastrointestinal abnormalities that may alter drug absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "such as malabsorption syndrome or major resection of the stomach or bowels",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "such as malabsorption syndrome or major resection of the stomach or bowels",
                    "criterion": "major resection of the stomach or bowels",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.",
            "criterions": [
                {
                    "exact_snippets": "dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1)",
                    "criterion": "measurable disease (dose-escalation cohort)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "measurable disease(s)"
                            }
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "RECIST criteria (Version 1.1)"
                        }
                    ]
                },
                {
                    "exact_snippets": "dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy",
                    "criterion": "measurable disease (dose-expansion cohort)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "measurable disease(s)"
                            }
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "RECIST criteria (version 1.1)"
                        },
                        {
                            "requirement_type": "lesion size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "biopsy capability",
                            "expected_value": "can be biopsied by core needle biopsy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fasting plasma glucose (FPG) =< 140 mg/dL or =< 7.8 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Fasting plasma glucose (FPG) =< 140 mg/dL or =< 7.8 mmol/L",
                    "criterion": "fasting plasma glucose (FPG)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 140,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 7.8,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the event of liver metastasis, AST/ALT =< 5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... =< 2.5 x ULN; in the event of liver metastasis, AST ... =< 5 ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 2.5 x ULN; in the event of liver metastasis, ... ALT =< 5 ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the event of liver metastasis, AST/ALT =< 5 ULN",
                    "criterion": "aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level in presence of liver metastasis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1.0 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1.0 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has an AR-positive and PTEN-positive tumor as determined by using Clinical Laboratory Improvement Amendments (CLIA) compliant assays to identify AR-positive and PTEN-positive disease (AR positivity is defined as >= 1% of nuclear staining, PTEN positivity is defined as > 0% of nuclear staining).",
            "criterions": [
                {
                    "exact_snippets": "AR-positive ... AR positivity is defined as >= 1% of nuclear staining",
                    "criterion": "AR (androgen receptor) expression in tumor",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "nuclear staining percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assay type",
                            "expected_value": "CLIA compliant"
                        }
                    ]
                },
                {
                    "exact_snippets": "PTEN-positive ... PTEN positivity is defined as > 0% of nuclear staining",
                    "criterion": "PTEN expression in tumor",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "nuclear staining percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assay type",
                            "expected_value": "CLIA compliant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For dose-escalation portion of study, patients must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.",
            "criterions": [
                {
                    "exact_snippets": "patients must be refractory to ... existing therapies known to provide clinical benefit for their condition",
                    "criterion": "refractoriness to existing therapies",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must be ... intolerant of existing therapies known to provide clinical benefit for their condition",
                    "criterion": "intolerance to existing therapies",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 4 weeks from prior therapy completion (including radiation and/or surgery to starting the study treatment) * Clinically and radiographically stable CNS tumor at the time of screening and not receive steroids and/or an enzyme inducing anti-epileptic mediations for brain metastasis",
            "criterions": [
                {
                    "exact_snippets": "At least 4 weeks from prior therapy completion (including radiation and/or surgery to starting the study treatment)",
                    "criterion": "time since prior therapy completion",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically and radiographically stable CNS tumor at the time of screening",
                    "criterion": "CNS tumor stability",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "radiographic stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not receive steroids and/or an enzyme inducing anti-epileptic mediations for brain metastasis",
                    "criterion": "use of steroids and/or enzyme inducing anti-epileptic medications for brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is >/= 18 years old.",
            "criterions": [
                {
                    "exact_snippets": "Patient is >/= 18 years old.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) =< 1 that the investigator believes is stable at the time of screening.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group performance status (ECOG PS) =< 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the investigator believes is stable at the time of screening",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absence of leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Absence of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total serum bilirubin =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total serum bilirubin =< 1.5 x ULN",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a life expectancy of at least 3 months in the opinion of the investigator.",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator opinion of life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has signed the informed consent form prior to the performance of any screening procedures and is able to comply with protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Patient has signed the informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is able to comply with protocol requirements",
                    "criterion": "protocol compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability to comply",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patient has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Patient has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) grade 1 or better ... from related side effects of any prior antineoplastic therapy.",
                    "criterion": "recovery from side effects of prior antineoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE v4.03 grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(except alopecia)",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception to recovery requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has uncontrolled diabetes.",
            "criterions": [
                {
                    "exact_snippets": "Patient has uncontrolled diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has any prior use of PI3K inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "any prior use of PI3K inhibitors",
                    "criterion": "PI3K inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a QT interval adjusted by the Fridericia formula (QTcF) > 480 msec on screening electrocardiogram (ECG).",
            "criterions": [
                {
                    "exact_snippets": "QT interval adjusted by the Fridericia formula (QTcF) > 480 msec on screening electrocardiogram (ECG)",
                    "criterion": "QTcF (QT interval adjusted by the Fridericia formula)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has completed radiotherapy within 2 weeks prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "Patient has completed radiotherapy within 2 weeks prior to treatment initiation.",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion_time_before_treatment_initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure requiring treatment (New York Heart Association grade >= 2), left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or ECHO.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure requiring treatment (New York Heart Association grade >= 2)",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or ECHO",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) < 3 months prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) < 3 months prior to screening.",
                    "criterion": "acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has had any systemic therapy within 2 weeks prior to initiating study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient has had any systemic therapy within 2 weeks prior to initiating study drug.",
                    "criterion": "systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to initiating study drug"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has any prior use of anti-androgen therapies.",
            "criterions": [
                {
                    "exact_snippets": "any prior use of anti-androgen therapies",
                    "criterion": "anti-androgen therapy use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and whose treatment cannot be either discontinued or switched to a different medication prior to starting treatment with the study drug.",
            "criterions": [
                {
                    "exact_snippets": "currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP)",
                    "criterion": "medication with risk of QT prolongation or TdP",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment cannot be either discontinued or switched to a different medication prior to starting treatment with the study drug",
                    "criterion": "ability to discontinue or switch medication",
                    "requirements": [
                        {
                            "requirement_type": "ability to discontinue or switch",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is currently receiving warfarin or other Coumarin-derived anticoagulant for treatment, prophylaxis, or other reasons. Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Patient is currently receiving warfarin or other Coumarin-derived anticoagulant for treatment, prophylaxis, or other reasons.",
                    "criterion": "current use of warfarin or other Coumarin-derived anticoagulant",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed.",
                    "criterion": "current use of heparin, low molecular weight heparin, or fondaparinux",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has known positive serology for human immunodeficiency virus (HIV).",
            "criterions": [
                {
                    "exact_snippets": "known positive serology for human immunodeficiency virus (HIV)",
                    "criterion": "HIV serology",
                    "requirements": [
                        {
                            "requirement_type": "serology result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a history of another malignancy within 2 years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix.",
            "criterions": [
                {
                    "exact_snippets": "history of another malignancy within 2 years prior to starting study treatment",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix",
                    "criterion": "history of basal cell carcinoma of the skin or carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "cured",
                                "excised"
                            ]
                        },
                        {
                            "requirement_type": "inclusion exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.",
            "criterions": [
                {
                    "exact_snippets": "known or suspected primary central nervous system (CNS) tumor",
                    "criterion": "primary central nervous system (CNS) tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS tumor involvement",
                    "criterion": "CNS tumor involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has known clinically significant cardiac disease or impaired cardiac function, such as:",
            "criterions": [
                {
                    "exact_snippets": "known clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "impaired cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a history of seizures or any condition that may predispose to seizures (e.g., prior cortical stroke, significant brain trauma) at any time in the past and/or a history of loss of consciousness or transient ischemic attack within 12 months of the cycle 1, day 1 visit.",
            "criterions": [
                {
                    "exact_snippets": "history of seizures",
                    "criterion": "seizures",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any condition that may predispose to seizures (e.g., prior cortical stroke, significant brain trauma) at any time in the past",
                    "criterion": "condition predisposing to seizures",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of loss of consciousness ... within 12 months of the cycle 1, day 1 visit",
                    "criterion": "loss of consciousness",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... transient ischemic attack within 12 months of the cycle 1, day 1 visit",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential have positive urine or serum pregnancy test no more than 7 days prior to starting study drug.",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive urine or serum pregnancy test no more than 7 days prior to starting study drug",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine pregnancy test",
                                "serum pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to starting study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.",
            "criterions": [
                {
                    "exact_snippets": "known hypersensitivity to any of the excipients of BYL719",
                    "criterion": "hypersensitivity to excipients of BYL719",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to any of the excipients of ... enzalutamide",
                    "criterion": "hypersensitivity to excipients of enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with patient's safety, provision of informed consent, or compliance with the study procedures.",
            "criterions": [
                {
                    "exact_snippets": "any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above)",
                    "criterion": "pre-existing medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric disorder",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that could interfere with patient's safety, provision of informed consent, or compliance with the study procedures",
                    "criterion": "other conditions interfering with safety, consent, or compliance",
                    "requirements": [
                        {
                            "requirement_type": "interference with safety, consent, or compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).",
            "criterions": [
                {
                    "exact_snippets": "impaired gastrointestinal (GI) function",
                    "criterion": "gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "GI disease that may significantly alter the absorption of oral BYL719",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "potential to alter absorption of oral BYL719",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative disease",
                    "criterion": "ulcerative disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled nausea",
                    "criterion": "nausea",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "vomiting",
                    "criterion": "vomiting",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "small bowel resection",
                    "criterion": "small bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has any other condition that would, in the investigators' judgment, preclude the patient's participation in the clinical study due to concerns about safety or compliance with clinical study procedures; e.g., infection/inflammation, intestinal obstruction, inability to swallow oral medication, social/psychological complications.",
            "criterions": [
                {
                    "exact_snippets": "any other condition that would, in the investigators' judgment, preclude the patient's participation in the clinical study due to concerns about safety or compliance with clinical study procedures",
                    "criterion": "other condition affecting participation",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment precludes participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "infection/inflammation",
                    "criterion": "infection or inflammation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to swallow oral medication",
                    "criterion": "inability to swallow oral medication",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social/psychological complications",
                    "criterion": "social or psychological complications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is currently receiving treatment with drugs known to be strong inhibitors or inducers of isoenzymes CYP3A or CYP2C8. The patient must have discontinued strong inducers for at least 1 week and must have discontinued strong inhibitors before the start of the study treatment. Switching to a different medication prior to initiation of the trial treatment is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Patient is currently receiving treatment with drugs known to be strong inhibitors or inducers of isoenzymes CYP3A or CYP2C8.",
                    "criterion": "current use of strong inhibitors or inducers of CYP3A or CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "The patient must have discontinued strong inducers for at least 1 week",
                    "criterion": "discontinuation of strong inducers of CYP3A or CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "time since discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have discontinued strong inhibitors before the start of the study treatment",
                    "criterion": "discontinuation of strong inhibitors of CYP3A or CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation before study treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has participated in a prior investigational study within 3 weeks prior to initiating study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patient has participated in a prior investigational study within 3 weeks prior to initiating study drug.",
                    "criterion": "participation in prior investigational study",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks prior to initiating study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or current evidence of clinically significant cardiac arrhythmias, atrial fibrillation, and/or conduction abnormality, e.g., congenital long QT syndrome, high-grade/complete arteriovenous blockage.",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of clinically significant cardiac arrhythmias",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "history or current evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of ... atrial fibrillation",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "history or current evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of ... conduction abnormality",
                    "criterion": "conduction abnormality",
                    "requirements": [
                        {
                            "requirement_type": "history or current evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congenital long QT syndrome",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "high-grade/complete arteriovenous blockage",
                    "criterion": "high-grade/complete arteriovenous blockage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a history of noncompliance to medical regimens or is unable to grant consent.",
            "criterions": [
                {
                    "exact_snippets": "history of noncompliance to medical regimens",
                    "criterion": "compliance to medical regimens",
                    "requirements": [
                        {
                            "requirement_type": "history of noncompliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to grant consent",
                    "criterion": "ability to grant consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Birth control pills, injections, implants, or patches.",
            "criterions": [
                {
                    "exact_snippets": "Birth control pills, injections, implants, or patches.",
                    "criterion": "birth control method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "pills",
                                "injections",
                                "implants",
                                "patches"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Two barrier methods (male condom and female diaphragm, cervical cap, or sponge) in combination with a spermicide.",
            "criterions": [
                {
                    "exact_snippets": "Two barrier methods (male condom and female diaphragm, cervical cap, or sponge) in combination with a spermicide.",
                    "criterion": "contraceptive method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "barrier method",
                                "barrier method",
                                "spermicide"
                            ]
                        },
                        {
                            "requirement_type": "combination",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgical birth control/sterilization (such as male vasectomy or female sterilization).",
            "criterions": [
                {
                    "exact_snippets": "Surgical birth control/sterilization (such as male vasectomy or female sterilization)",
                    "criterion": "surgical birth control/sterilization",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "male vasectomy",
                    "criterion": "male vasectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "female sterilization",
                    "criterion": "female sterilization",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intrauterine devices (IUDs).",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine devices (IUDs)",
                    "criterion": "intrauterine device (IUD) use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Highly effective contraception must be used by both sexes during the study and must be continued for 6 months after the last dose of study treatment. (Women of not childbearing potential: post-menopausal [age > 55 years with cessation of menses > 12 months or < 55 years but not spontaneous menses for at least 2 years or < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of \"postmenopausal range\" for the laboratory involved] or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).",
            "criterions": [
                {
                    "exact_snippets": "Highly effective contraception must be used by both sexes during the study and must be continued for 6 months after the last dose of study treatment.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of not childbearing potential: post-menopausal [age > 55 years with cessation of menses > 12 months",
                    "criterion": "post-menopausal status (age > 55 years)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 55,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "cessation of menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "< 55 years but not spontaneous menses for at least 2 years",
                    "criterion": "post-menopausal status (age < 55 years, no spontaneous menses)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "spontaneous menses absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "< 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L)",
                    "criterion": "post-menopausal status (age < 55 years, recent menses, currently amenorrheic, postmenopausal gonadotropin levels)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "spontaneous menses within past year",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current amenorrhea",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "luteinizing hormone level",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "IU/L"
                            }
                        },
                        {
                            "requirement_type": "follicle-stimulating hormone level",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "postmenopausal estradiol levels (< 5 ng/dL)",
                    "criterion": "postmenopausal estradiol level",
                    "requirements": [
                        {
                            "requirement_type": "estradiol level",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "according to the definition of \"postmenopausal range\" for the laboratory involved",
                    "criterion": "postmenopausal laboratory range",
                    "requirements": [
                        {
                            "requirement_type": "laboratory-defined postmenopausal range",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "hysterectomy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "bilateral salpingectomy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "bilateral oophorectomy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential are not willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study. Highly effective contraception is defined as:",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study",
                    "criterion": "contraception or abstinence willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use highly effective contraception or abstain from heterosexual activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are breast-feeding.",
            "criterions": [
                {
                    "exact_snippets": "Female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Patient has disease that is hormone-receptor positive (estrogen receptor [ER] and/or progesterone receptor [PR] positive [+], HER-2/neu negative [-]) or triple-negative (ER/PR/HER-2/neu -).",
            "criterions": [
                {
                    "exact_snippets": "hormone-receptor positive (estrogen receptor [ER] and/or progesterone receptor [PR] positive [+])",
                    "criterion": "hormone receptor status",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "progesterone receptor status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER-2/neu negative [-]",
                    "criterion": "HER-2/neu status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "triple-negative (ER/PR/HER-2/neu -)",
                    "criterion": "triple-negative status",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "progesterone receptor status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "HER-2/neu status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}